Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines that unlock high-impact protein targets long-considered undruggable. Leveraging over a decade of proprietary data, laboratory innovations, and AI- and physics-based algorithms, the company has developed a new class of stabilized, cell-penetrant alpha-helical peptides - Helicons™ - capable of modulating intracellular proteins that are inaccessible to traditional drug modalities.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/12/26 | $305,000,000 | Series F |
ARCH Venture Partners Cormorant Asset Management Fidelity Management & Research Company Frazier Life Sciences General Catalyst Partners Janus Henderson Investors Nextech Invest RA Capital Management Soleus Capital VenBio | undisclosed |
